Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379
Jan Martin Berke, Pascale Dehertogh, Karen Vergauwen, Wendy Mostmans, Koen Vandyck, Pierre Raboisson, Frederik Pauwels
Abstract
of 876 nM) and reduced antigen levels (secondary MOA). Adding JNJ-6379 to PHHs 4 or 5 days postinfection reduced extracellular HBV DNA and did not prevent cccDNA formation. Time-of-addition PHH studies revealed that JNJ-6379 most likely interfered with postentry processes. Collectively, these data demonstrate that JNJ-6379 has dual MOAs in the early and late steps of the HBV life cycle, which is different from the MOA of nucleos(t)ide analogues. JNJ-6379 is in development for chronic hepatitis B treatment and may translate into higher HBV functional cure rates.
Topics & Concepts
cccDNACapsidHepatitis B virusVirologyBiologyViral life cycleViral replicationMinichromosomeVirusMolecular biologyDNAHBsAgBiochemistryChromatinHepatitis B Virus StudiesHepatitis C virus researchBacteriophages and microbial interactions